Phase II Randomised Trial to Assess Progression of Carcinoid Heart Disease in Patients Treated With Lutathera Therapy Compared to Best Supportive Care.
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms CHARRT
- 09 Aug 2020 Planned number of patients changed from 30 to 20.
- 03 Aug 2020 Planned initiation date changed from 1 Jun 2020 to 1 Oct 2020.
- 16 Apr 2020 Planned initiation date changed from 1 Nov 2019 to 1 Jun 2020.